Latest International Markets News

Wellnex Life Limited reported a 36% rise in Q2 FY25 cash receipts and record monthly sales, while advancing its dual listing on the London Stock Exchange and expanding into the UK market.

Oakridge International Limited reports a strong quarterly performance driven by increased contracted orders, strategic partnerships, and technological innovation, positioning the company for sustained growth into 2025.

IODM Limited reported a decline in cash reserves to $461,000 for the December quarter, while projecting revenue growth through new university client onboarding in the UK and North America.

Eden Innovations Ltd reports a striking 158% increase in US OptiBlend® sales for Q2 FY25, alongside expanding international traction for its EdenCrete® products and strategic property sales aimed at debt reduction.

Origin Energy's December 2024 Quarterly Report reveals a 3% revenue increase in its Integrated Gas segment despite a slight production dip, while Octopus Energy continues rapid customer growth, becoming the UK's largest retailer.

Control Bionics has delivered its strongest US sales quarter in years, nearing US$1 million in revenue, while broadening its market footprint with new commercial agreements and cost optimizations.

ImpediMed Limited has reported record quarterly revenue and cash receipts for Q2 FY25, alongside significant growth in reimbursement coverage and a robust sales pipeline, signaling strong momentum in its digital health platform business.

Orbital Corporation Ltd reports a strong quarterly update with 29 engines delivered, a debt-free balance sheet, and significant R&D grant funding supporting new engine development.

OncoSil Medical has secured new distribution agreements across key international markets and achieved critical regulatory milestones, while raising $8 million to fuel its growth in pancreatic cancer treatment.

Bio-Gene Technology Limited has advanced its bio-insecticide pipeline with two U.S. Department of Defense grants totaling A$3 million, alongside key regulatory and production milestones for Flavocide® and Qcide®.

Audeara Ltd reports a 70% jump in Q2 FY25 cash receipts, driven by new product launches and a major contract with Avedis Zildjian. The company’s expansion into Taiwan and international markets signals a promising growth trajectory.

Clever Culture Systems Ltd has achieved a key cashflow break-even milestone in Q4 2024, driven by strong sales growth from major pharmaceutical clients including AstraZeneca and Bristol Myers Squibb. The company is also advancing its product line with a new APAS® Contact Plate capability set for mid-2025 launch.